In his current consultancy position, Low specialises in strategic market access, patient engagement, and life sciences and healthcare policy.
Prior to founding his consultancy business, Low established, and served for 20 years as CEO of, Myeloma UK (Edinburgh, UK) – an organisation credited with ensuring that myeloma patients in the UK can access novel treatments by advocating for solution-oriented approaches to the way drugs are made available on the NHS.
Low is also a Senior Visiting Research Fellow at the University of Leeds Medical School (Leeds, UK) and was awarded an OBE for services to charity in 2012.